{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:26:11Z","timestamp":1788175571215,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T00:00:00Z","timestamp":1391731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00345-014-1255-z","type":"journal-article","created":{"date-parts":[[2014,2,6]],"date-time":"2014-02-06T03:26:51Z","timestamp":1391657211000},"page":"1127-1132","source":"Crossref","is-referenced-by-count":26,"title":["Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies"],"prefix":"10.1007","volume":"32","author":[{"given":"Matthias","family":"Oelke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Mamoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,7]]},"reference":[{"key":"1255_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37\u201349","journal-title":"Urology"},{"key":"1255_CR2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1464-410X.2003.04527.x","volume":"92","author":"KS Coyne","year":"2003","unstructured":"Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E (2003) The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92:948\u2013954","journal-title":"BJU Int"},{"key":"1255_CR3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","volume":"57","author":"KA Tikkinen","year":"2010","unstructured":"Tikkinen KA, Johnson TM, Tammela TL et al (2010) Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 57:488\u2013496","journal-title":"Eur Urol"},{"key":"1255_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1464-410X.2011.10175.x","volume":"108","author":"JP Weiss","year":"2011","unstructured":"Weiss JP, Blaivas JG, Bliwise DL et al (2011) The evaluation and treatment of nocturia: a consensus statement. BJU Int 108:6\u201321","journal-title":"BJU Int"},{"key":"1255_CR5","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","volume":"53","author":"CG Stief","year":"2008","unstructured":"Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236\u20131244","journal-title":"Eur Urol"},{"key":"1255_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-5347(05)67961-X","volume":"163","author":"JP Weiss","year":"2000","unstructured":"Weiss JP, Blaivas JG (2000) Nocturia. J Urol 163:5\u201312","journal-title":"J Urol"},{"key":"1255_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118\u2013140","journal-title":"Eur Urol"},{"key":"1255_CR8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1742-1241.2012.02960.x","volume":"66","author":"L Kingery","year":"2012","unstructured":"Kingery L, Martin ML, Naegeli AN, Khan S, Viktrup L (2012) Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. Int J Clin Pract 66:883\u2013890","journal-title":"Int J Clin Pract"},{"key":"1255_CR9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","volume":"180","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228\u20131234","journal-title":"J Urol"},{"key":"1255_CR10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","volume":"60","author":"H Porst","year":"2011","unstructured":"Porst H, Kim ED, Casabe AR et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105\u20131113","journal-title":"Eur Urol"},{"key":"1255_CR11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","volume":"61","author":"M Oelke","year":"2012","unstructured":"Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917\u2013925","journal-title":"Eur Urol"},{"key":"1255_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1743-6109.2011.02504.x","volume":"9","author":"RB Egerdie","year":"2012","unstructured":"Egerdie RB, Auerbach S, Roehrborn CG et al (2012) Tadalafil 2.5 or 5\u00a0mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9:271\u2013281","journal-title":"J Sex Med"},{"key":"1255_CR13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.urology.2013.05.005","volume":"82","author":"H Porst","year":"2013","unstructured":"Porst H, Oelke M, Goldfischer ER et al (2013) Efficacy and safety of tadalafil 5\u00a0mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 82:667\u2013673","journal-title":"Urology"},{"key":"1255_CR14","unstructured":"(2010) Cialis [package insert]. http:\/\/pi.lilly.com\/us\/cialis-pi.pdf"},{"key":"1255_CR15","unstructured":"(2013) Summary of product characteristics (Cialis). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000436\/WC500026318.pdf"},{"key":"1255_CR16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2004.07.016","volume":"46","author":"S Madersbacher","year":"2004","unstructured":"Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547\u2013554","journal-title":"Eur Urol"},{"key":"1255_CR17","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/jsm.12212","volume":"10","author":"H Porst","year":"2013","unstructured":"Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L (2013) Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 10:2044\u20132052","journal-title":"J Sex Med"},{"key":"1255_CR18","first-page":"18","volume-title":"Current aspects in diagnosis and treatment of nocturia","author":"KAO Tikkinen","year":"2012","unstructured":"Tikkinen KAO, Johnson TM II, Cartwright R (2012) Prevalence and bother of nocturia. In: Oelke M, van Kerrebroeck PEV (eds) Current aspects in diagnosis and treatment of nocturia, 1st edn. UNI-MED-Verlag, Bremen, pp 18\u201326","edition":"1"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1255-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-014-1255-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1255-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:40:13Z","timestamp":1559036413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-014-1255-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,7]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1255"],"URL":"https:\/\/doi.org\/10.1007\/s00345-014-1255-z","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718269373.793494116","asserted-by":"object"}]},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,7]]}}}